G Hartz | PubMed Health

PubMed1987

Familial glomerulonephritis.

Between 1970 and 1984, the diagnosis of glomerulonephritis was made in 860 patients on the basis of a nephritic sediment and/or renal biopsy; of these patients, 86 (10%) had at least one first-degree relative with glomerulonephritis. These patients originated from 45 families and 1674 family members were screened; 172 had glomerulonephritis, of whom 101 could be classified. The diagnostic breakdown of the 101 patients showed that 50.5% had classical Alport's syndrome; 21.8% had atypical forms; 17.8% had familial IgA glomerulonephritis; 1.9% had focal segmental glomerulosclerosis with Wolff-Parkinson-White syndrome; and 7.9% had benign familial haematuria. The proportion of patients with glomerulonephritis who had familial disease was higher than expected. The family history is an important point to consider in the examination of patients with glomerulonephritis.

Adolescent↗

PubMed1981

Dopaminergic (DA) systems: their role in pathological neurobehavioral symptoms.

Two established dopamine (DA) systems (i.e., the nigrostriatal and the mesolimbic-mesocortical) are the focus of this article. Their neuroanatomy is briefly outlined to relate neurochemical with neurobehavioral events and alterations in DA-affected systems with the behavioral consequence. Selected theories and major ideas related to DA systems and their implicated role in neurobehavioral symptoms that have emerged over the last decade are included. Correlations with behavioral consequences of disturbances in DA systems lack clarity as to precisely known clinical effects relating to human behavioral and motor acts. The purpose of this article is to review selectively the literature pertaining to two of the six major DA mechanisms. The principal question addressed in this article is, "How do DA mechanisms promote neurobehavioral consequences such as the symptoms of schizophrenia?" Other topics covered include Parkinson's disease, Huntington's chorea, and intracranial self-stimulation drive-reward mechanisms. These clinical features and their possible underlying basis are discussed in terms of evidence suggesting that DA neurotransmitter alterations are likely to be several steps removed from a primary causal locus, which has more than one biochemical or neurotransmitter mechanism.

Animals↗